Long-term survival following chemoradiotherapy for postoperative recurrence of hilar cholangiocarcinoma

Read full text
Authors: Kazuki Asakura, Takahiro Einama, Kazuki Kobayashi, Hanae Shinada, Naoto Yonamine, Takazumi Tsunenari, Mikiya Takao, Saburo MATSUBARA, Kazuyuki Oyama, Yoji Kishi
Cited by: 0

Abstract

Standard treatment for metastatic biliary tract cancer is systemic chemotherapy, not local therapy, such as surgery or radiation therapy. This is because long-term survival is not expected with local therapy. We present the case of a 49-year-old man who underwent extended right hepatectomy with extrahepatic bile duct resection for hilar cholangiocarcinoma. Postoperative adjuvant chemotherapy with oral S-1 for six months was completed. At 20 months post-operation, para-aortic lymphadenopathy was detected, and endoscopic ultrasound-guided biopsy confirmed lymph node recurrence. Gemcitabine and cisplatin were administered for six months, resulting in partial tumor regression. As no other lesions were identified, radiotherapy with a total dose of 55 Gy in 22 fractions was performed. At 37 months following the completion of radiotherapy, the patient remained disease-free based on imaging. This case suggests that the addition of local radiotherapy to systemic chemotherapy may be beneficial for patients with oligometastatic recurrence of hilar cholangiocarcinoma.

Fields of Study & Subjects

Cholangiocarcinoma and Gallbladder Cancer Studies Pediatric Hepatobiliary Diseases and Treatments Gallbladder and Bile Duct Disorders

Publication details

Journal / source
Clinical Journal of Gastroenterology
Volume
19
Issue
2
Pages
395–399
Publication date
31 January 2026
Language
EN